Eisai has initiated a rolling submission to the FDA for a subcutaneous autoinjector of LEQEMBI for weekly maintenance dosing in early Alzheimer's disease, following Fast Track designation.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.